Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS)

被引:0
|
作者
A. Cantù Rajnoldi
S. Fenu
G. Kerndrup
E. R. van Wering
C. M. Niemeyer
I. Baumann
机构
[1] Istituti Clinici di Perfezionamento,Dip.to di Medicina di Laboratorio
[2] Azienda Ospedaliera San Giovanni-Addolorata UOD Ematologica,Institute of Pathology
[3] Odense University Hospital,Division of Hematology and Oncology, Department of Pediatrics and Adolescent Medicine
[4] Dutch Childhood Leukemia Study Group,Institute of Pathology
[5] University Hospital Freiburg,undefined
[6] University Erlangen-Nuremberg,undefined
来源
Annals of Hematology | 2005年 / 84卷
关键词
Myelodysplastic syndrome; Morphological features of dysplasia;
D O I
暂无
中图分类号
学科分类号
摘要
In the absence of genetic abnormalities, the diagnoses of myelodysplastic syndromes (MDS) is primarily based on the presence of dysplasia in blood and marrow cells. Currently, there is no standardized approach to evaluate dysplasia. International cooperative study groups like the European Working Group on MDS in Childhood (EWOG-MDS) depend, however, on a concordance in diagnoses by their national reference centres for morphology. In EWOG-MDS, the morphological diagnoses of all cases enrolled from Scandinavia, the Netherlands, Germany, the Czech Republic, Austria and Italy are established by five experienced pathologists or hematologists cooperating in a morphology board. To study their concordance in evaluating myelodysplastic disorders, members of the morphology board initiated blinded reviews of smears of blood and bone marrow aspirates of known cases. Four features of dysplasia in granulopoiesis, erythropoiesis and megakaryopoiesis were assessed on May–Grünwald–Giemsa stained smears. In a final review of six blinded cases, good concordance for these features was achieved among the five observers. Accurately defined and restrictively applied cellular features of dysplasia are an important tool to improve and ensure the concordance in the diagnosis of MDS among investigators. For cooperative groups, agreement on the evaluation of the morphological assessment of dysplasia is a prerequisite.
引用
收藏
页码:429 / 433
页数:4
相关论文
共 50 条
  • [41] Hematopoietic Stem Cell Transplantation (HSCT) after a myeloablative conditioning regimen in children with refractory cytopenia (RC): Results of a retrospective analysis from the EWOG-MDS group
    Locatelli, Franco
    Noellke, Peter
    Fisher, Alexandra
    Bader, Peter
    Bernardo, Maria Ester
    Bergstraesser, Eva
    Hasle, Henrik
    van den Heuvel-Eibrink, Marry
    Korthof, Elisabeth
    Stary, Jan
    Strahm, Brigitte
    Zintl, Felix
    Sedlacek, Petr
    Zecca, Marco
    Niemeyer, Charlotte M.
    BLOOD, 2007, 110 (11) : 81A - 81A
  • [42] Survival Analysis of Myelodysplastic Syndrome (MDS) Patients with Abnormal Karyotype - A Single Group Experience
    Nadeem, Muhammad
    Galili, Naomi
    Mumtaz, Muhammad
    Daya, Peter
    Cheskis, Jason
    Raza, Azra
    BLOOD, 2012, 120 (21)
  • [43] Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry
    Madry, Krzysztof
    Lis, Karol
    Fenaux, Pierre
    Bowen, David
    Symeonidis, Argiris
    Mittelman, Moshe
    Stauder, Reinhard
    Cermak, Jaroslav
    Sanz, Guillermo
    Hellstrom-Lindberg, Eva
    Langemeijer, Saskia
    Malcovati, Luca
    Germing, Ulrich
    Holm, Mette Skov
    Guerci-Bresler, Agnes
    Culligan, Dominic
    Sanhes, Laurence
    Kotsianidis, Ioannis
    van Marrewijk, Corine
    Crouch, Simon
    de Witte, Theo
    Smith, Alex
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (04) : 451 - 461
  • [44] Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
    Bertrums, Eline J. M.
    Zwaan, C. Michel
    Hasegawa, Daisuke
    de Haas, Valerie
    Reinhardt, Dirk N.
    Locatelli, Franco
    de Moerloose, Barbara
    Dworzak, Michael
    Buijs, Arjan
    Smisek, Petr
    Kolenova, Alexandra
    Pronk, Cornelis Jan
    Klusmann, Jan-Henning
    Carbone, Ana
    Ferster, Alina
    Antoniou, Evangelia
    Meshinchi, Soheil
    Raimondi, Susana C.
    Niemeyer, Charlotte M.
    Hasle, Henrik
    van den Heuvel-Eibrink, Marry M.
    Goemans, Bianca F.
    HAEMATOLOGICA, 2022, 107 (03) : 759 - 764
  • [45] Venetoclax and Azacytidine Therapy in High-Risk Myelodysplastic Syndromes: A Retrospective Evaluation of a RealWorld Experience. Latin-American MDS Group - Glam
    Iastrebner, Marcelo
    Crisp, Renee Leonor
    Ovilla, Roberto
    Gomez-De Leon, Andres
    Puente, Adriana Karola
    Duarte, Fernando Barroso
    Velloso, Elvira D. R. P.
    Gusmao, Breno
    Varela, Ana
    Boada, Matilde
    Grille, Sofia
    BLOOD, 2022, 140 : 12329 - 12330
  • [46] Acute myeloid leukemia (AML) - Type chemotherapy for newly diagnosed children with myelodysplastic syndrome (MDS): A Japanese childhood MDS study group trial MDS99.
    Ohtsuka, Y
    Manabe, A
    Okamura, J
    Kojima, S
    Ohara, A
    Tuchida, M
    Ikuta, K
    Hibi, S
    Kawa, K
    Yabe, M
    Watanabe, A
    Ueda, K
    Nakazawa, S
    Miyazaki, S
    Nakahata, T
    BLOOD, 2004, 104 (11) : 265B - 265B
  • [47] Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
    Komrokji, Rami S.
    Al Ali, Najla H.
    Sallman, David
    Padron, Eric
    DeZern, Amy E.
    Barnard, John
    Roboz, Gail J.
    Garcia-Manero, Guillermo
    List, Alan
    Steensma, David P.
    Sekeres, Mikkael A.
    CANCER MEDICINE, 2021, 10 (02): : 447 - 453
  • [48] The Effect of Oral Iron Chelator Deferiprone on Iron Overload and Oxidative Stress in Patients with Myelodysplastic Syndromes: A Study by the Israeli MDS Working Group
    Merkel, Drorit
    Soffer, Shelly
    Filanovsky, Kalman
    Braester, Andrei
    Fibach, Eitan
    Dana, Mutaz
    Ofran, Yishai
    Greenbaum, Uri
    Nagler, Arnon
    Amitai, Irina
    Mittelman, Moshe
    ACTA HAEMATOLOGICA, 2024, 147 (04) : 427 - 434
  • [49] Quality of life in myelodysplastic syndromes (MDS): Results from US & European patient forums.
    Heptinstall, Kathy
    BLOOD, 2006, 108 (11) : 741A - 741A
  • [50] Flow cytometry in myelodysplastic syndromes: A report from an international consortium and the European LeukemiaNet Working Group
    Zhijian, X.
    Tianjiao, Z.
    LEUKEMIA RESEARCH, 2013, 37 : S45 - S45